M&A / Deals Vertex buys Crinetics for $10bn in endocrinology drive PharmaphorumVertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.Rare DiseaseRead full story pharminent July 7, 2026 (Last updated: July 8, 2026) Pharmaphorum Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly. Rare Disease Read full story Post navigation Previous: EC approves AbbVie’s Tepkinly combination for follicular lymphomaNext: Vera’s TRUTAKNA Wins FDA Accelerated Approval for IgA Nephropathy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026